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Background
It has been hypothesized that genetic alteration at the cellular level may have a significant 
effect on cellular mechanisms controlling the proliferation and apoptosis of Langerhans 
cells (LCs). 
Methods
We examined whether p16 protein expression can be used to predict the outcome of 
Langerhans cell histiocytosis (LCH). Archival paraffin blocks from children diagnosed with 
LCH and followed at the Asan Medical Center and Chungnam National University Hospital 
between March 1998 and February 2008 were studied. 
Results
Slides were stained with p16 antibody and evaluated semi-quantitatively using the follow-
ing scale: negative, no staining; ±, weakly positive; 1+, staining similar to lymphocytes 
surrounding the LCs; 2+, stronger staining than lymphocytes; 3+, much stronger stain-
ing than lymphocytes. Negative and ± groups were assigned to a lower expression group 
(LEG) and the 1+, 2+, and 3+ groups were assigned to a higher expression group (HEG). 
The median age of the 51 patients (24 girls, 27 boys) was 49 (range, 0.6-178) months, 
and LCH was diagnosed based on CD1a positivity.  p16 protein was expressed to varying 
degrees in all but one specimen. There was a greater tendency toward multisystem dis-
ease, risk organ involvement, and relapse in the HEG than in the LEG. 
Conclusion
The p16 protein may have a significant effect on cellular mechanisms controlling the pro-
liferation and apoptosis of LCs, and thus may influence the clinical outcome and prognosis 
of LCH.
Key Words Genes, p16, Histiocytosis, Langerhans cells, Immunohistochemistry
Correspondence to
Jong Jin Seo, M.D.
Division of Pediatrics 
Hematology/Oncology, Department of 
Pediatrics, University of Ulsan College of 
Medicine & Asan Medical Center, 388-1, 





Ⓒ2010 Korean Society of Hematology
INTRODUCTION
  Langerhans cell histiocytosis (LCH) has a variable clinical 
spectrum, ranging from isolated bone or skin lesions to 
life-threatening multisystem involvement [1]. Despite the 
markedly poorer prognosis of patients with multisystem dis-
ease and the involvement of risk organs, there are no clear 
morphological differences among lesions observed in the 
different clinical categories [2]. LCH has a wide spectrum 
of clinical features, although the cause of the disease is ob-
scure [1-3]. In order to treat LCH appropriately, it is essential 
to investigate the disturbances in cell proliferation and apop-
totic pathways that may lead to LCH, and to identify the 
molecules associated with multisystem disease and disease 
progression [3, 4].
  The clonality of cell populations observed in LCH suggests 
a genetic basis for this disease [2, 4-6]. Genetic alterations 
at the cellular level may disrupt mechanisms controlling 
the proliferation and apoptosis of Langerhans cells (LCs). 
Previous studies have examined the expression and func-
tional significance of LC-specific genes [2, 4-6]. However, 
only a few studies have examined the genes involved in 
the cell cycle of LCH cells, such as p53, MDM2, p16, p21, 
ki-67, and Bcl-2 [4-6]. Thus, much remains unclear regarding 
the expression of these genes and their clinical significance Korean J Hematol 2010;45:247-52.
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Fig. 1. Light micrographs of LCH lesions after immunohistochemical staining (×400). Scattered morphologically positive LCs are shown. A 
semi-quantitative evaluation was made using the following grading system: negative, no staining; ±, weakly positive (A) 1+, staining similar to 
lymphocytes surrounding the LCs (B) 2+, stronger staining than lymphocytes (C) 3+, much stronger staining than lymphocytes (D).
in LCH.
  A series of structurally related enzymes regulate pro-
gression of the cell cycle from the G1 to S phase: cyclin 
regulates the activation of cyclin-dependent kinases (CDKs); 
CDKs regulate retinoblastoma protein (pRb) and induce the 
release of E2F transcription factors and the expression of 
genes required for the S phase; and cyclin-CDK complexes 
are negatively regulated by a family of kinase inhibitors 
[7, 8]. The p16
INK4 (CDKN2A) gene located on chromosome 
9p21 encodes the p16 protein, which inhibits CDKs and 
blocks cell cycle progression [7-9]. Notably, p16 is often 
mutated or inactivated in primary tumors, including leuke-
mias, lymphomas, gliomas, lung carcinomas, colon cancer 
and many cancer cell lines, and is thus regarded as a tumor 
suppressor gene [10-13].
  This report describes the clinicopathologic features of LCH 
with regard to the p16 expression of LCs in biopsy specimens, 
which we used to determine whether p16 expression is a 
relevant clinical risk factor in LCH patients.
MATERIALS AND METHODS
1. Patients
    Formalin-fixed, paraffin-embedded biopsy specimens 
from children with LCH diagnosed between March 1987 
and February 2008 at the Asan Medical Center and Chung-
nam National University Hospital were examined using p16 
immunohistochemistry. We analyzed the relationship be-
tween p16 protein expression and clinical features. Single- 
system involvement was defined as uni- or multifocal in-
volvement of a single organ system, whereas multisystem 
involvement was defined as the involvement of multiple 
organ systems, with or without organ dysfunction [1-3]. 
Risk organs were the liver, spleen, lung, and the hema-
topoietic system [1-3]. Patient medical records were re-
viewed retrospectively for organ involvement at diagnosis, 
disease course, relapse, and late sequelae.Korean J Hematol 2010;45:247-52.
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Table 1. Clinical manifestations according to the immunohisto-
chemical grade.
LEG (N=14) HEG (N=37)
Sex, N (%)
M 6 (42.9) 21 (56.8)
F 8 (57.1) 16 (43.2)
Age, N (%)
＜2 years 4 (28.6) 13 (35.1)
≥2 years 10 (71.4) 24 (64.9)
Risk organ involvement, N (%)
Yes 0 (0) 5 (13.5)
No 14 (100) 32 (86.5)
System involvement, N (%)
Single  13 (92.9) 28 (75.7)
Multiple 1 (7.1) 9 (24.3)
Relapse, N (%) 1 (7.1) 9 (24.3)
Progression, N (%) 0 (0) 1 (2.7)
Abbreviations: LEG, lower expression group; HEG, higher expre-
ssion group.
2. Immunohistochemistry
  Immunohistochemistry was performed on specimens from 
all cases of LCH using standard laboratory methods. Briefly, 
5-mm sections were cut from representative tissue blocks 
and mounted on silane-coated slides, deparaffinized in xy-
lene, and then rehydrated through p16 (clone JC8; Neo 
Markers, Fremont, CA). Immunohistochemical staining was 
evaluated by an experienced pathologist blinded to the clin-
ical outcome.
3. Grading
  Grading was performed in fields in which LCs were present 
in compact sheets. LCs were identified morphologically and 
immunohistochemically by comparing the section stained 
with the relevant antibody with adjacent hematoxylin and 
eosin (H&E)- and CD1a-stained sections. Staining was con-
sidered positive when it was cytoplasmic or nuclear. At least 
500 LCs were counted on each slide using a grid eyepiece 
at ×400 magnification. The numbers of LCs expressing the 
relevant antigen were then counted in the same fields and 
the result was expressed as the degree of staining in LCs 
compared to that in lymphocytes surrounding the LCs. A 
semi-quantitative evaluation was made using the following 
grading system: negative, no staining; ±, weakly positive; 
1+, staining similar to lymphocytes surrounding the LCs; 
2+, stronger staining than lymphocytes; 3+, much stronger 
staining than lymphocytes (Fig. 1). For cases with biopsies 
from more than one lesion, a mean grade was calculated.
4. Statistical analysis
  All statistical analyses were performed using SPSS 13.0 
(SPSS, Chicago, IL). We attempted to fit an exact multivariate 
model to the data, but the sample size was too small to 
achieve convergence. We were cautious about interpreting 
non-significant results because of the low statistical power 
of a small sample size. The parameters of the patients at 
diagnosis were compared between groups using the 
Mann-Whitney exact test. The event-free survival rate was 
estimated using the Kaplan-Meier method. An event was 
defined as the occurrence of relapse, progression, or death. 
The difference in survival rates between groups according 
to p16 expression status was compared using the log-rank 
test.  P-value＜0.05 was regarded as statistically significant.
RESULTS
1. Patient characteristics
  Slides from 70 patients (32 girls, 38 boys) were available 
for immunohistochemistry, but only 51 patients (24 girls, 
27 boys) were included in thi s  s t u d y .  T h e  d a t a  f r o m  1 9  
patients were not suitable for evaluation because the quality 
of staining was poor, the tumor cells were too difficult to 
differentiate, or no data at diagnosis were available. The 
median age of the 51 patients was 49 (range, 0.6-178) months. 
The diagnosis of LCH was made by demonstrating patho-
logical LCs and a characteristic infiltrate. LCs were identified 
by a positive immunohistochemical reaction to S100 and 
CD1a antibodies. The organs involved included bone, skin, 
liver, lung, bone marrow, pituitary gland, and lymph nodes. 
Bone involvement with or without the involvement of anoth-
er site was the most common manifestation and was observed 
in 90.2% of the cases (46/51). Forty-one of the patients 
(80.4%) were diagnosed with single-system disease and 10 
patients (19.6%) with multisystem disease. Five patients 
(9.8%) had risk organ involvement at the time of diagnosis.
2. p16 immunohistochemistry
  All but 2 cases (96.1%) showed diffuse nuclear and cyto-
plasmic staining of pathologic LCs. Multinucleate giant cells 
also showed variable reactivity. According to our grading 
system, 2 patients were negative, 12 were ±, 14 were 1+, 
13 were 2+, and 10 were 3+. To determine whether the 
level of p16 expression can be used to predict the outcome 
of LCH, the immunohistochemical expression of p16 was 
divided into lower expression (negative and ±) and higher 
expression (1+, 2+, and 3+) groups (LEG and HEG, re-
spectively).
  Fourteen of the 51 patients (27.5%) fell within the LEG 
and 37 patients fell within the HEG (72.5%). All 5 patients 
with risk organ involvement were included in the HEG. 
Patients in the HEG also showed a greater tendency of multi-
system involvement and relapse, although the difference 
was not significant (Table 1). Bone involvement was the 
most common manifestation in both groups, and there were 
2 (14.3%) and 5 (13.5%) patients with multifocal involvement 
in the LEG and HEG, respectively. Although the LEG showed 
involvement of the skin and pituitary gland (low-risk organs), 
the HEG showed primarily involvement of the liver, bone 
marrow, lung, and lymph nodes, all of which, except the 
lymph nodes, are risk organs (Table 2). The median follow-up 
duration was 79 months (range, 15-147). The probability Korean J Hematol 2010;45:247-52.
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Table 2. Organ involvement according to the immunohistoche-
mical grade.
LEG (N=14) HEG (N=37)
Bone, N (%)
Unifocal 12 (85.7) 32 (86.5)
Multifocal 2 (14.3) 5 (13.5)
Skin, N (%) 1 (7.1) 4 (10.8)
Hematopoietic system, N (%) 0 (0) 1 (2.7)
Liver, N (%) 0 (0) 3 (8.1)
Lung, N (%) 0 (0) 2 (5.4)
Pituitary gland, N (%) 1 (7.1) 0 (0)
Lymph nodes, N (%) 0 (0) 4 (10.8)
Abbreviations: LEG, lower expression group; HEG, higher expre-
ssion group.
Fig. 2. Six-year event-free survival (EFS) rate according to immuno-
histochemical grade. The probability of 6-year EFS for LEG patients was
92.9±6.9%, whereas that for HEG patients was 70.3±8.1%. The 
difference was not significant according to the log-rank test. of 6-year EFS for the LEG patients was 92.9±6.9%, whereas 
that for the HEG patients was 70.3±8.1%; however, the differ-
ence was not statistically significant according to the log-rank 
test (Fig. 2).
DISCUSSION
  The clinical manifestations of LCH vary considerably and 
can involve nearly every organ of the body [1-3]. Conventio-
nal histology alone can give only a presumptive diagnosis 
of LCH. The course of the disease is unpredictable, varying 
from spontaneous regression and resolution to rapid pro-
gression and death or recurrence [1-3]. Patients with lo-
calized disease generally have a good prognosis and need 
minimal or even no treatment. In contrast, multisystem dis-
ease, which is particularly frequent in children younger than 
2 years, carries a risk of poor outcome [1, 3, 14]. In one 
large study of 101 children with LCH, the overall survival 
rate was 79%, 74%, and 71% at 1, 3, and 5 years, respectively. 
Conversely, in patients with liver or spleen involvement, 
the 1-year survival was 33% and the 5-year survival was 
just 25% [15]. Therefore, factors influencing the outcome 
of LCH must be identified to prevent or facilitate the treat-
ment of disease progression and relapse.
  The detailed pathogenetic mechanism of LCH remains 
unknown. Furthermore, it is not yet understood why some 
patients develop single-system disease, whereas others devel-
op fatal multisystem lesions. The finding that essentially 
all cases of LCH exhibit clonal LCs suggests a primary genetic 
alteration [2, 4, 16]. There is much debate as to whether 
the observation of clonality in lesional LCs proves that LCH 
is a ‘neoplastic’ disorder, because clonality is one of the 
key features characterizing nearly all cancers. Nevertheless, 
clonality alone is insufficient to make a diagnosis of cancer, 
as there are examples of clonal ‘reactive’ lesions [3, 17].
  Several studies have suggested that genetic mechanisms 
play a role in LCH pathogenesis [2, 4-6]. This possibility 
was further supported by Chikwava et al. [18], who analyzed 
fractional allelic loss (FAL) across a number of tumor sup-
pressor genes, comparing FAL at various clinical stages of 
LCH and in LCH cases involving organs at various degrees. 
They found that the mean FAL in multisystem LCH was 
significantly higher than that in single-system LCH. Further-
more, FAL was also significantly higher in children with 
high-risk or special-site LCH than in children with low-risk 
LCH. These findings suggest that genetic alterations, specifi-
cally an increased frequency of loss of heterozygosity (LOH) 
in high-stage, high-risk forms of the disease, lead to disease 
progression, potentially due to alterations in tumor sup-
pressor genes also involved in tumorigenesis [18, 19].
  Because a genetic component is suspected to play a role 
in the pathogenesis of LCH, several groups have investigated 
LC-specific genes and their functional significance in LCH 
[2, 4-6]. However, few studies have examined genes involved 
in the cell cycle of LCH cells. The presence of clonal cell 
populations, as observed in most LCH lesions, may result 
from a genetic alteration that affects cellular mechanisms 
controlling proliferation and apoptosis [2, 4, 18]. Several 
genetic markers of LCH have been identified in previous 
studies, but their prognostic significance remains unclear.
  The p16-Rb pathway is important for detecting DNA dam-
age and inducing cell cycle arrest [7, 9, 10]. This pathway 
was previously found to be active in LCH lesions [5]. The 
p16 protein is an important tumor suppressor that is in-
activated in a large proportion (＞30%) of human tumors 
[7-11]. This tumor suppressor gene inhibits the CDK4-6 kin-
ases, thus preventing CDK-mediated phosphorylation of Rb 
and, subsequently, cell cycle progression [20]. The tumor 
suppressor protein Rb, which associates with several tran-
scription factors in its unphosphorylated or hypophosphory-
lated form, silences their transactivation functions. The most 
important transcription factors that Rb silences are the E2F 
proteins, which activate the expression of important cell 
cycle proteins, such as cyclins E and A. When Rb is phos-Korean J Hematol 2010;45:247-52.
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phorylated, it will no longer bind E2F, leading to the activa-
tion of DNA synthesis [7, 8, 20]. In our study, p16 was 
expressed diffusely in all but 1 specimen, and patients with 
specimens showing overexpression had a greater likelihood 
of poorer prognosis.
  Bcl-2 is considered to be a negative regulator of apoptosis, 
as it inhibits cell death by evoking cell survival signals [21, 
22]. Schouten et al. [5] reported that 29 of the 30 LCH 
cases were positive for Bcl-2, ranging from limited focal 
reactivity in some cases to strong diffuse staining in others. 
Savell et al. [23] also observed Bcl-2 protein expression in 
11 of 13 cases of LCH; notably, 5 cases showed a germline 
configuration of the Bcl-2 gene. Furthermore, Amir et al. 
[2] have founded that Bcl-2 is highly expressed in patients 
with multisystem disease compared with single-system di-
sease. The overexpression of Bcl-2 may play a role in the 
activation of p53 and p16 and the subsequent arrest of apopto-
sis [24-26]. However, it is unclear why Bcl-2 expression 
is so extensive in LCH lesions, and other markers associated 
with p16 overexpression should be studied to clarify the 
pathogenesis of LCH. In immunohistochemical experiments 
such as ours, it is difficult to assess the coexpression of markers 
within such a heterogeneous cell population. Consequently, 
the interpretation of these findings requires a cautionary 
approach.
  This study of the expression of p16 in LCH aimed to 
define genetic and functional characteristics of LCH that 
may account for the pathogenesis of the disease. We observed 
diffuse expression of the p16 protein in both single- and 
multisystem lesions in patients with LCH. A greater tendency 
to relapse was observed in the HEG than in the LEG. The 
HEG had a greater tendency toward multisystem disease 
and risk organ involvement. However, the association be-
tween p16 expression and patient age was not significant. 
Due to the relatively low incidence of risk organ involvement 
or relapse in this study cohort, we were unable to detect 
a clear statistical difference regarding these parameters be-
tween the LEG and HEG. Nevertheless, p16 expression may 
be involved in the pathogenesis of LCH and have predictive 
power regarding clinical outcome and prognosis. However, 
additional immunohistochemical analyses examining the 
functional relevance of this protein and a number of other 
genetic markers are required to prove this hypothesis. More 
detailed information regarding genetic markers will help 
to clearly delineate the different entities of LCH, and may 
facilitate the development of an advanced classification sys-
tem as a basis for selecting an appropriate therapeutic 
approach.
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